Neumora Therapeutics(NMRA) Newsfilter·2025-03-15 13:29Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit claims that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about their clinical trials [4]. - The firm encourages anyone with information regarding Neumora's conduct to contact them, including whistleblowers and former employees [8]. Group 2: Company Performance and Stock Impact - On January 2, 2025, Neumora announced that its experimental treatment failed in the Phase III Koastal-1 trial, showing no difference from a placebo [5]. - Following this announcement, Neumora's stock price dropped 81%, closing at $1.97 per share [6].